01—Abstract
Summary
Summary of the 8-K filed February 22, 2024. Cited figures are marked; the original filing is the authoritative source.
BridgeBio Pharma, Inc. (Nasdaq: BBIO) furnished a press release reporting its fourth quarter and full year 2023 financial results and business updates.
The headline regulatory milestone is the submission and acceptance of a New Drug Application to the FDA for acoramidis for transthyretin amyloid cardiomyopathy (ATTR-CM), with a PDUFA date of November 29, 2024, and a Marketing Authorization Application accepted by the EMA. Full-year 2023 revenue was $9.3 milliona versus $77.6 million in 2022, while net loss attributable to common stockholders of BridgeBio was $643.2 million, or $3.95 per share, compared with $481.2 million, or $3.26 per share, in 2022. Net cash used in operating activities was $527.7 million for the year.
The company reported $392.6 millionb in cash, cash equivalents and short-term restricted cash at December 31, 2023, down from $466.2 million a year earlier. Management cited $449.8 million of net proceeds from equity financings during 2023. Recent capital actions include up to $1.25 billion from Blue Owl and CPP Investments, comprising $500 million in cash payable upon FDA approval of acoramidis in exchange for a 5% royalty on future global net sales of acoramidis, and a $450 million credit facility from Blue Owl that refinanced existing senior secured credit and extends maturity from 2026 to 2029, subject to certain conditions.
Pipeline progress includes PROPEL 3 for infigratinib in achondroplasia, which continues to enroll with full enrollment expected in 2024, and a Japan licensing deal with Kyowa Kirin that provides a $100 millionc upfront payment plus royalties up to the high-twenties percent. FORTIFY (BBP-418 for LGMD2I) and CALIBRATE (encaleret for ADH1) are also enrolling, with full enrollment expected in 2024 and topline CALIBRATE data expected in 2025. The company stated it expects to read out Phase 1/2 data in congenital adrenal hyperplasia later in 2024.
02—Key points
Key Highlights
- Acoramidis NDA accepted by the FDA with a PDUFA date of November 29, 2024; MAA for acoramidis accepted by the EMA for ATTR-CM.
- Full-year 2023 revenue of $9.3 million, down from $77.6 million in 2022, primarily due to license revenue recognized in 2022 under the Navire-BMS License Agreement.
- Full-year 2023 net loss attributable to common stockholders of BridgeBio of $643.2 million, or $3.95 per share, versus $481.2 million, or $3.26 per share, in 2022.
- Total operating costs and expenses of $616.7 million for 2023, including R&D expenses that rose by $55.2 million to advance the pipeline.
- Cash, cash equivalents and short-term restricted cash of $392.6 million at December 31, 2023, versus $466.2 million (including marketable securities) at December 31, 2022; net cash used in operating activities was $527.7 million.
- Up to $1.25 billion in capital from Blue Owl and CPP Investments, including $500 million in cash upon FDA approval of acoramidis in exchange for a 5% royalty, and a $450 million credit facility extending maturity from 2026 to 2029.
- Kyowa Kirin license for infigratinib in Japan for skeletal dysplasias, with a $100 million upfront payment and royalties up to the high-twenties percent.
03—Questions
Frequently Asked Questions
What is the most important regulatory event disclosed in this filing?
The company's New Drug Application for acoramidis for ATTR-CM was accepted for review by the FDA with a PDUFA date of November 29, 2024. The Marketing Authorization Application for acoramidis was also accepted for review by the European Medicines Agency. The filings are based on the Phase 3 ATTRibute-CM study, which the company says met its primary endpoint with a win ratio of 1.8 and a p-value below 0.0001.
How did BridgeBio's revenue and net loss change in 2023?
Revenue was $9.3 million for the year ended December 31, 2023, compared with $77.6 million in 2022, a decrease the company attributed mainly to license revenue recognized in 2022 under the Navire-BMS License Agreement. Net loss attributable to common stockholders of BridgeBio was $643.2 million, or $3.95 per share, compared with $481.2 million, or $3.26 per share, in 2022.
How is the company funding its operations?
The company cites up to $1.25 billion from Blue Owl and CPP Investments. This includes $500 million in cash, available upon FDA approval of acoramidis, in exchange for a 5% royalty on future global net sales of acoramidis, and a $450 million Blue Owl credit facility that refinanced existing senior secured credit and extends maturity from 2026 to 2029 subject to certain conditions. During 2023, net proceeds from equity financings were $449.8 million.
What cash position did BridgeBio report at year-end 2023?
The company reported $392.6 million in cash, cash equivalents and short-term restricted cash as of December 31, 2023, compared with $466.2 million of cash, cash equivalents, marketable securities and short-term restricted cash a year earlier. Net cash used in operating activities for 2023 was $527.7 million.
What are the next expected pipeline milestones?
The company expects full enrollment of PROPEL 3 (infigratinib for achondroplasia) and CALIBRATE (encaleret for ADH1) in 2024, and full enrollment of the FORTIFY interim analysis population (BBP-418 for LGMD2I) in 2024. Topline data from CALIBRATE are expected in 2025. Management also said it hopes to read out Phase 1/2 data in congenital adrenal hyperplasia later in 2024.
04—Continue